Kumar Neil 4
4 · BridgeBio Pharma, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
BridgeBio (BBIO) CEO Neil Kumar Sells 80,000 Shares
What Happened
Neil Kumar, CEO of BridgeBio Pharma, sold a total of 80,000 BridgeBio shares in open‑market/private transactions on June 4–5, 2026. The sales totaled approximately $5,413,286 (average ≈ $67.67/share). Individual tranches ranged from about $65.15 up to $69.51 per share across the reported trades. These were sales (not purchases or option exercises).
Key Details
- Transaction dates: June 4–5, 2026; filing date: June 8, 2026 (Form 4 accession 0001470831-26-000523). Filing appears timely under Section 16 (within required business‑day window).
- Total shares sold: 80,000; approximate proceeds: $5.41 million; weighted average sale price ≈ $67.67 per share.
- Price range: per footnotes, sales occurred across roughly $65.145 to $69.51 per share (footnotes F2–F9 give weighted‑average subranges; detailed per‑price breakdown available upon request).
- 10b5‑1 plan: At least some sales were effected pursuant to a Rule 10b5‑1 plan adopted March 31, 2025 (F1).
- Beneficial ownership disclaimer: The reporting person disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest (F3).
- Transaction code: S = Sale. No purchases or option exercises reported in this filing.
Context
Sales executed under a pre‑arranged 10b5‑1 plan are typically routine and do not necessarily reflect the insider’s short‑term view of the company. Because these were outright sales (not buys or option exercises followed by immediate sale), they are not usually interpreted as a bullish signal. If you want the exact per‑price breakdown or the post‑transaction holdings reported on the full Form 4, that information can be retrieved from the SEC filing or requested from the filer/Commission staff as noted in the footnotes.
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-06-04$65.72/sh−2,200$144,584→ 553,486 total(indirect: By Trust) - Sale
Common Stock
[F1][F4][F3]2026-06-04$66.72/sh−1,429$95,347→ 552,057 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F3]2026-06-04$67.74/sh−15,921$1,078,454→ 536,136 total(indirect: By Trust) - Sale
Common Stock
[F1][F6][F3]2026-06-04$68.27/sh−450$30,721→ 535,686 total(indirect: By Trust) - Sale
Common Stock
[F1][F2][F3]2026-06-04$65.72/sh−2,200$144,584→ 4,356,247 total(indirect: By Trust) - Sale
Common Stock
[F1][F4][F3]2026-06-04$66.72/sh−1,429$95,347→ 4,354,818 total(indirect: By Trust) - Sale
Common Stock
[F1][F5][F3]2026-06-04$67.74/sh−15,921$1,078,452→ 4,338,897 total(indirect: By Trust) - Sale
Common Stock
[F1][F6][F3]2026-06-04$68.27/sh−450$30,721→ 4,338,447 total(indirect: By Trust) - Sale
Common Stock
[F1][F7][F3]2026-06-05$67.20/sh−7,147$480,271→ 528,539 total(indirect: By Trust) - Sale
Common Stock
[F1][F8][F3]2026-06-05$67.88/sh−8,437$572,744→ 520,102 total(indirect: By Trust) - Sale
Common Stock
[F1][F9][F3]2026-06-05$68.96/sh−4,416$304,524→ 515,686 total(indirect: By Trust) - Sale
Common Stock
[F1][F7][F3]2026-06-05$67.20/sh−7,148$480,338→ 4,331,299 total(indirect: By Trust) - Sale
Common Stock
[F1][F8][F3]2026-06-05$67.88/sh−8,437$572,744→ 4,322,862 total(indirect: By Trust) - Sale
Common Stock
[F1][F9][F3]2026-06-05$68.96/sh−4,415$304,455→ 4,318,447 total(indirect: By Trust)
Holdings
- 243,327
Common Stock
Footnotes (9)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F2]Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- [F4]Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F7]Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F8]Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F9]Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Signature
/s/ Will Solis, Attorney-in-Fact|2026-06-08